Expert opinions on positron emission tomography and computed tomography imaging in lymphoma.
Revised guidelines for the staging and response criteria of Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL) were recently published to include the expanding role of positron emission tomography/computed tomography (PET/CT) using (18)F-fluoro-2-deoxyglucose. Here, we discuss the new guidelines and the need for standardized PET acquisition and interpretation in HL and NHL. We also discuss how the role for CT is evolving in the process of making treatment decisions and provide insight on how best to standardize the use of PET/CT for making therapeutic choices.
Delbeke
Dominique
D
Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Stroobants
Sigrid
S
de Kerviler
Eric
E
Gisselbrecht
Christian
C
Meignan
Michel
M
Conti
Peter S
PS
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019788:Fluorodeoxyglucose F18; D006689:Hodgkin Disease / Q000000981:diagnostic imaging* / Q000188:drug therapy; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging* / Q000188:drug therapy; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000379:methods; D017410:Practice Guidelines as Topic; D011379:Prognosis; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed / Q000379:methods*; D016896:Treatment Outcome
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18